BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 20411323)

  • 1. Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.
    Pierce LJ; Phillips KA; Griffith KA; Buys S; Gaffney DK; Moran MS; Haffty BG; Ben-David M; Kaufman B; Garber JE; Merajver SD; Balmaña J; Meirovitz A; Domchek SM
    Breast Cancer Res Treat; 2010 Jun; 121(2):389-98. PubMed ID: 20411323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
    Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
    Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer.
    Wan Q; Su L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    JAMA Netw Open; 2021 Apr; 4(4):e216259. PubMed ID: 33890992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is breast-conserving therapy adequate in BRCA 1/2 mutation carriers? The radiation oncologist's point of view.
    Vallard A; Magné N; Guy JB; Espenel S; Rancoule C; Diao P; Deutsch E; Rivera S; Chargari C
    Br J Radiol; 2019 May; 92(1097):20170657. PubMed ID: 30810334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.
    Nilsson MP; Hartman L; Kristoffersson U; Johannsson OT; Borg A; Henriksson K; Lanke E; Olsson H; Loman N
    Breast Cancer Res Treat; 2014 Oct; 147(3):571-8. PubMed ID: 25187270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers.
    Bernstein-Molho R; Laitman Y; Galper S; Jacobson G; Boursi B; Gal-Yam EN; Kaufman B; Friedman E; Kaidar-Person O
    Int J Radiat Oncol Biol Phys; 2021 Apr; 109(5):1332-1340. PubMed ID: 33259931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
    Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
    J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contralateral breast cancer and tumor recurrence in BRCA1/2 carriers and non-carriers at a high risk of hereditary breast cancer after bilateral mastectomy.
    Allué Cabañuz M; Domingo Bretón M; Chóliz Ezquerro J; Arribas Del Amo MD; Güemes Sánchez AT
    Cir Esp (Engl Ed); 2020 Dec; 98(10):612-617. PubMed ID: 32505558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined breast conservation therapy versus mastectomy for BRCA mutation carriers - A systematic review and meta-analysis.
    Davey MG; Davey CM; Ryan ÉJ; Lowery AJ; Kerin MJ
    Breast; 2021 Apr; 56():26-34. PubMed ID: 33582622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
    van den Broek AJ; Schmidt MK; van 't Veer LJ; Oldenburg HSA; Rutgers EJ; Russell NS; Smit VTHBM; Voogd AC; Koppert LB; Siesling S; Jobsen JJ; Westenend PJ; van Leeuwen FE; Tollenaar RAEM
    Ann Surg; 2019 Aug; 270(2):364-372. PubMed ID: 29727326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.
    Fountzilas E; Konstantopoulou I; Vagena A; Apostolou P; Papadimitriou C; Christodoulou C; Tryfonopoulos D; Manousou K; Delimitsou A; Papamentzelopoulou M; Fountzilas G; Yannoukakos D; Fostira F
    Clin Breast Cancer; 2020 Apr; 20(2):152-159. PubMed ID: 31980407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer treatment in mutation carriers: surgical treatment.
    Biglia N; D'Alonzo M; Sgro LG; Tomasi Cont N; Bounous V; Robba E
    Minerva Ginecol; 2016 Oct; 68(5):548-56. PubMed ID: 26822896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.
    Menes TS; Terry MB; Goldgar D; Andrulis IL; Knight JA; John EM; Liao Y; Southey M; Miron A; Chung W; Buys SS
    Breast Cancer Res Treat; 2015 Jun; 151(3):653-60. PubMed ID: 25975955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants.
    Liu X; Wang Y; Cao K; Yao L; Hu L; Sun J; Zhang J; Xu Y; Xie Y
    Breast Cancer Res Treat; 2023 May; 199(1):25-33. PubMed ID: 36930346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis.
    Valachis A; Nearchou AD; Lind P
    Breast Cancer Res Treat; 2014 Apr; 144(3):443-55. PubMed ID: 24567198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.
    Seynaeve C; Verhoog LC; van de Bosch LM; van Geel AN; Menke-Pluymers M; Meijers-Heijboer EJ; van den Ouweland AM; Wagner A; Creutzberg CL; Niermeijer MF; Klijn JG; Brekelmans CT
    Eur J Cancer; 2004 May; 40(8):1150-8. PubMed ID: 15110878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review.
    Hallam S; Govindarajulu S; Huckett B; Bahl A
    Clin Oncol (R Coll Radiol); 2015 Sep; 27(9):527-35. PubMed ID: 26113392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
    Golshan M; Miron A; Nixon AJ; Garber JE; Cash EP; Iglehart JD; Harris JR; Wong JS
    Am J Surg; 2006 Jul; 192(1):58-62. PubMed ID: 16769276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.